All of us at Genzyme want to express our continued commitment to you, the Gaucher community. We have been committed to research and development for treatment of Gaucher disease for over 20 years. We are determined to continue to serve the Gaucher community in every way we can, which includes:
Genzyme Care Coordination
To speak with a Genzyme Case Manager in your area, please call
Medical Affairs Liaisons
The Gaucher Registry
Genzyme Medical Information
Genzyme Clinical Trials-eliglustat tartrate (formerly Genzyme 112638)
Genzyme is also developing an investigational oral compound as an alternative for adult patients with Gaucher disease type 1. The first clinical study of eliglustat tartrate (a phase II clinical study) has completed its primary analysis of 52 weeks.
1) The ENGAGE study will assign 36 patients to receive either eliglustat tartrate or a placebo for 9 months; patients may then choose to continue treatment with eliglustat tartrate in the extension study until it is approved by the FDA. This study is open to adult Gaucher disease 1 patients who have not received enzyme replacement in the past 12 months or oral Gaucher treatments in the past 6 months.
2) The ENCORE study will assign 186 patients to receive either eliglustat tartrate or Cerezyme® treatment for 1 year; patients may then choose to continue treatment with eliglustat tartrate in the extension study until it is approved by the FDA. The ENCORE study is open to adult GD1 patients who have been treated with Cerezyme® for at least 3 years and have not had a dose reduction or treatment interruption lasting more than 6 consecutive months.
For more information on these clinical trials of eliglustat tartrate including a list of US sites, please go to www.clinicaltrials.gov, contact the study coordinator listed, talk to your own physician, or call Genzyme Medical Information at 1-800-745-4447, option 2.